loader from loading.io

Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni Kura Oncology

Empowered Patient Podcast

Release Date: 06/25/2024

ACOs Using Value-Based Care  to Improve Outcomes and Reduce Hospital Readmissions with Dr. Tom Kim Sound Long-Term Care Management TRANSCRIPT show art ACOs Using Value-Based Care to Improve Outcomes and Reduce Hospital Readmissions with Dr. Tom Kim Sound Long-Term Care Management TRANSCRIPT

Empowered Patient Podcast

Tom Kim, Chief Medical Officer at Sound Long-Term Care Management, discusses the role of accountable care organizations, ACOs, in improving healthcare for the long-term care population. The unique complexities and challenges of these patients include multiple medical conditions, frequent hospitalizations, and fragmented care.  By using predictive analytics, telemedicine, and value-based care principles to deliver more coordinated care, patients are avoiding hospitalizations, receiving higher-quality care, and experiencing reduced costs. Tom explains, "So, in essence, an accountable care...

info_outline
ACOs Using Value-Based Care  to Improve Outcomes and Reduce Hospital Readmissions with Dr. Tom Kim Sound Long-Term Care Management show art ACOs Using Value-Based Care to Improve Outcomes and Reduce Hospital Readmissions with Dr. Tom Kim Sound Long-Term Care Management

Empowered Patient Podcast

Tom Kim, Chief Medical Officer at Sound Long-Term Care Management, discusses the role of accountable care organizations, ACOs, in improving healthcare for the long-term care population. The unique complexities and challenges of these patients include multiple medical conditions, frequent hospitalizations, and fragmented care.  By using predictive analytics, telemedicine, and value-based care principles to deliver more coordinated care, patients are avoiding hospitalizations, receiving higher-quality care, and experiencing reduced costs. Tom explains, "So, in essence, an accountable care...

info_outline
Healthcare Supply Chain Management Goes Digital With Lisa Israelovitch AssistIQ TRANSCRIPT show art Healthcare Supply Chain Management Goes Digital With Lisa Israelovitch AssistIQ TRANSCRIPT

Empowered Patient Podcast

Lisa Israelovitch, Co-Founder and CEO of AssistIQ, is addressing the challenges in healthcare supply chain management caused by a lack of accurate data on supplies used across the care facility, which leads to operational inefficiencies and financial losses. The previous methods of tracking have often been manual and unreliable, involving product stickers, barcode readers, and manual data entry.  Using computer vision and AI to automatically see, track, and document every product used is improving data accuracy, saving clinicians' time, enabling inventory tracking and product expiration...

info_outline
Healthcare Supply Chain Management Goes Digital With Lisa Israelovitch AssistIQ show art Healthcare Supply Chain Management Goes Digital With Lisa Israelovitch AssistIQ

Empowered Patient Podcast

Lisa Israelovitch, Co-Founder and CEO of AssistIQ, is addressing the challenges in healthcare supply chain management caused by a lack of accurate data on supplies used across the care facility, which leads to operational inefficiencies and financial losses. The previous methods of tracking have often been manual and unreliable, involving product stickers, barcode readers, and manual data entry.  Using computer vision and AI to automatically see, track, and document every product used is improving data accuracy, saving clinicians' time, enabling inventory tracking and product expiration...

info_outline
Shape-Shifting Device Extends Stroke Treatment to Smaller Brain Vessels with Ronen Eckhouse Rapid Medical TRANSCRIPT show art Shape-Shifting Device Extends Stroke Treatment to Smaller Brain Vessels with Ronen Eckhouse Rapid Medical TRANSCRIPT

Empowered Patient Podcast

Ronen Eckhouse, Co-Founder and CEO of Rapid Medical, identifies the limitations of current stroke treatments, which are primarily effective for large vessel occlusions.  The Rapid Medical TIGERTRIEVER device is designed to safely and effectively treat strokes and remove clots in smaller vessels deeper in the brain.  The unique adjustability of the device allows physicians to control the size and force during a procedure, allowing for precise and safer clot removal in complex anatomies. Ronen explains, "So the quicker or the less time there is between the stroke and the ability to...

info_outline
Shape-Shifting Device Extends Stroke Treatment to Smaller Brain Vessels with Ronen Eckhouse Rapid Medical show art Shape-Shifting Device Extends Stroke Treatment to Smaller Brain Vessels with Ronen Eckhouse Rapid Medical

Empowered Patient Podcast

Ronen Eckhouse, Co-Founder and CEO of Rapid Medical, identifies the limitations of current stroke treatments, which are primarily effective for large vessel occlusions.  The Rapid Medical TIGERTRIEVER device is designed to safely and effectively treat strokes and remove clots in smaller vessels deeper in the brain.  The unique adjustability of the device allows physicians to control the size and force during a procedure, allowing for precise and safer clot removal in complex anatomies. Ronen explains, "So the quicker or the less time there is between the stroke and the ability to...

info_outline
Short RNA Therapy Targets Survival Genes in Treatment for Multiple Cancer Types with Robert Schickel NUAgo Therapeutics show art Short RNA Therapy Targets Survival Genes in Treatment for Multiple Cancer Types with Robert Schickel NUAgo Therapeutics

Empowered Patient Podcast

Robert Schickel, Chief Executive Officer at NUAgo Therapeutics, is developing a cancer therapy using short RNAs to target and disrupt interconnected survival genes in cancer cells. The therapy has been shown to be non-toxic to healthy cells, which have high levels of microRNAs, whereas cancer cells downregulate microRNAs to become metastatic. This is a systems-biology therapeutic approach that targets the entire survival network of a cell, making it independent of specific mutations or pathways and potentially applicable to the vast majority of solid tumors. Robert explains, "NUAgo is a...

info_outline
Nuclear Oncology and Advanced Molecular Imaging  Transforming Prostate Cancer Treatment with Dr. Babak Saboury United Theranostics TRANSCRIPT show art Nuclear Oncology and Advanced Molecular Imaging Transforming Prostate Cancer Treatment with Dr. Babak Saboury United Theranostics TRANSCRIPT

Empowered Patient Podcast

Dr. Babak Saboury, Chief Scientific and Innovation Officer and Physician Founder of United Theranostics, discusses the emergence of nuclear oncology as the fourth pillar of cancer care.  United Theranostics is combining advanced molecular imaging and radiopharmaceutical therapies to identify a cancer cell's unique fingerprint and then delivering targeted radiation, reducing side effects by sparing healthy cells. Molecular imaging can serve as a unifying map for guiding a collaborative, multimodal approach to treating a range of cancers.  Babak explains, "I can just very quickly tell...

info_outline
Nuclear Oncology and Advanced Molecular Imaging Transforming Prostate Cancer Treatment with Dr. Babak Saboury United Theranostics show art Nuclear Oncology and Advanced Molecular Imaging Transforming Prostate Cancer Treatment with Dr. Babak Saboury United Theranostics

Empowered Patient Podcast

Dr. Babak Saboury, Chief Scientific and Innovation Officer and Physician Founder of United Theranostics, discusses the emergence of nuclear oncology as the fourth pillar of cancer care.  United Theranostics is combining advanced molecular imaging and radiopharmaceutical therapies to identify a cancer cell's unique fingerprint and then delivering targeted radiation, reducing side effects by sparing healthy cells. Molecular imaging can serve as a unifying map for guiding a collaborative, multimodal approach to treating a range of cancers.  Babak explains, "I can just very quickly tell...

info_outline
Local Drug Delivery Technology Transforming  Pancreatic Cancer Treatment with Shaun Bagai RenovoRx TRANSCRIPT show art Local Drug Delivery Technology Transforming Pancreatic Cancer Treatment with Shaun Bagai RenovoRx TRANSCRIPT

Empowered Patient Podcast

Shaun Bagai, CEO of RenovoRx,  has designed a drug-delivery platform to treat hard-to-reach chemo-resistant tumors such as pancreatic cancer by delivering chemotherapy directly to the tumor site. The RenovoCath device increases the drug concentration in the tumor while significantly reducing systemic toxicities and side effects. The technology is not intended to replace the traditional approach using systemic chemotherapy and radiation, but to achieve better results in tumors with low blood supply that prevent drugs from reaching their target in sufficient concentrations. Shaun explains,...

info_outline
 
More Episodes

Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene expression and promoting healthy cell development opens the door to potential combination therapy, where menin inhibitors could be layered onto existing treatments for various cancers related to menin independence.

Mollie explains, "In oncology, we have gotten good at treating the end state, but cancer has many, many causes with a common final endpoint to the way the cells look. So, it's many, many different diseases all at once. We've learned and are learning that with better technology and a better understanding of cancer in general we can identify not just how to stop the end state but how to stop it from starting."

"That's where ziftomenib comes in. Ziftomenib addresses key mutations that when they occur, are what cause the development of cancer. So you're able to shut down the development and force the cells to develop normally rather than waiting until they're already diseased and killing them with chemotherapy or some other cytotoxic agent."

"There is a protein complex that we refer to as the menin MLL complex, which goes rogue when something unusual happens in the cell. For example, that could be an NPM1 mutation. That could be a KMT2A rearrangement. Those are two things that are well-known to happen within AML diseases. It could also be a SETD2 RUNX1 mutation. So many types of mutations could happen that could cause this machinery to go rogue within the cell. And that complex causes genes to become active at levels and at times that are abnormal."

#KuraOncology #Ziftomenib #MeninInhibitors #PrecisionMedicine #BTD #AML

KuraOncology.com

Download the transcript here

Kura Oncology